Summary

The global blood screening market is witnessing consistent growth as healthcare providers and regulatory authorities place increasing emphasis on blood safety and quality assurance. Blood screening is a vital component of modern healthcare systems, ensuring that donated blood is free from infectious agents before transfusion. With the rising demand for blood transfusions across surgical procedures, trauma care, and chronic disease management, blood screening technologies have become indispensable for hospitals, blood banks, and diagnostic laboratories worldwide.

Market Insights

The blood screening market is valued at USD 3.7 billion in 2026 and is projected to reach USD 6.85 billion by 2033, expanding at a compound annual growth rate of 9.2% during the forecast period. This growth is driven by increasing investments in diagnostic infrastructure, the adoption of advanced testing technologies, and strict enforcement of blood safety regulations. The market continues to evolve with a strong focus on improving detection accuracy, reducing testing time, and enhancing overall operational efficiency.

Key Market Drivers

A major factor driving the blood screening market is the rising prevalence of infectious diseases that pose risks to blood transfusion safety. The growing number of blood donations and transfusion procedures globally has intensified the need for reliable and standardized screening solutions. Regulatory mandates requiring comprehensive screening of donated blood further support market expansion. In addition, technological advancements that enable early detection of pathogens and reduce false results are strengthening confidence in modern blood screening systems.

Business Opportunity Analysis

Significant business opportunities exist in the development and adoption of advanced screening technologies that offer higher sensitivity and automation. Diagnostic companies are increasingly focusing on innovative solutions that streamline workflows and reduce operational burdens for blood banks and laboratories. Emerging markets present strong growth potential due to expanding healthcare infrastructure, increasing awareness of transfusion safety, and rising government initiatives to improve diagnostic access. Partnerships, mergers, and collaborations among key stakeholders are expected to accelerate market growth and expand global reach.

Regional Analysis

North America remains a leading region in the blood screening market, supported by advanced healthcare systems, strong regulatory frameworks, and high adoption of innovative diagnostic technologies. Europe also represents a substantial share, driven by established transfusion services and a strong focus on patient safety and quality standards. The Asia Pacific region is anticipated to record rapid growth due to rising healthcare investments, growing population, and increasing awareness regarding blood safety. Latin America and the Middle East and Africa are steadily progressing, supported by improving diagnostic capabilities and government-led healthcare initiatives.

Competitive Landscape

The blood screening market features a competitive landscape with the presence of several global and regional players. Market participants are emphasizing research and development, product launches, and strategic expansions to strengthen their market positions. Continuous innovation and adherence to evolving regulatory requirements remain key strategies among leading companies. The competitive environment encourages technological advancement and ensures the availability of high-quality screening solutions across diverse healthcare settings.

Key Players

• Abbott Laboratories

• Roche Diagnostics

• Siemens Healthineers

• Thermo Fisher Scientific

• Bio Rad Laboratories

• Danaher Corporation (Beckman Coulter & Cepheid)

• Becton, Dickinson and Company (BD)

• BioMérieux

• Grifols, S.A.

• Ortho Clinical Diagnostics

• Hologic, Inc.

• QuidelOrtho Corporation

• F. Hoffmann La Roche Ltd.

• PerkinElmer, Inc.

• Sysmex Corporation

Market Segmentation

By Technology:

• Nucleic Acid Amplification Test (NAT)

• ELISA

• Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)

• Next Generation Sequencing

• Western Blotting

By Product:

• Nucleic Acid Amplification Test (NAT)

• ELISA

• Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)

• Next Generation Sequencing

• Western Blotting

By Region:

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East and Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Blood Screening Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2026
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. COVID-19 Impact Analysis
2.5. Porter's Fiver Forces Analysis
2.6. Impact of Russia-Ukraine Conflict
2.7. PESTLE Analysis
2.8. Regulatory Analysis
2.9. Price Trend Analysis
2.9.1. Current Prices and Future Projections, 2025-2033
2.9.2. Price Impact Factors
3. Global Blood Screening Market Outlook, 2020-2033
3.1. Global Blood Screening Market Outlook, by Technology, Value (US$ Bn), 2020-2033
3.1.1. Nucleic Acid Amplification Test (NAT)
3.1.2. ELISA
3.1.3. Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)
3.1.4. Next Generation Sequencing
3.1.5. Western Blotting
3.2. Global Blood Screening Market Outlook, by Product, Value (US$ Bn), 2020-2033
3.2.1. Reagent
3.2.2. Instrument
3.3. Global Blood Screening Market Outlook, by Region, Value (US$ Bn), 2020-2033
3.3.1. North America
3.3.2. Europe
3.3.3. Asia Pacific
3.3.4. Latin America
3.3.5. Middle East & Africa
4. North America Blood Screening Market Outlook, 2020-2033
4.1. North America Blood Screening Market Outlook, by Technology, Value (US$ Bn), 2020-2033
4.1.1. Nucleic Acid Amplification Test (NAT)
4.1.2. ELISA
4.1.3. Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)
4.1.4. Next Generation Sequencing
4.1.5. Western Blotting
4.2. North America Blood Screening Market Outlook, by Product, Value (US$ Bn), 2020-2033
4.2.1. Reagent
4.2.2. Instrument
4.3. North America Blood Screening Market Outlook, by Country, Value (US$ Bn), 2020-2033
4.3.1. U.S. Blood Screening Market Outlook, by Technology, 2020-2033
4.3.2. U.S. Blood Screening Market Outlook, by Product, 2020-2033
4.3.3. Canada Blood Screening Market Outlook, by Technology, 2020-2033
4.3.4. Canada Blood Screening Market Outlook, by Product, 2020-2033
4.4. BPS Analysis/Market Attractiveness Analysis
5. Europe Blood Screening Market Outlook, 2020-2033
5.1. Europe Blood Screening Market Outlook, by Technology, Value (US$ Bn), 2020-2033
5.1.1. Nucleic Acid Amplification Test (NAT)
5.1.2. ELISA
5.1.3. Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)
5.1.4. Next Generation Sequencing
5.1.5. Western Blotting
5.2. Europe Blood Screening Market Outlook, by Product, Value (US$ Bn), 2020-2033
5.2.1. Reagent
5.2.2. Instrument
5.3. Europe Blood Screening Market Outlook, by Country, Value (US$ Bn), 2020-2033
5.3.1. Germany Blood Screening Market Outlook, by Technology, 2020-2033
5.3.2. Germany Blood Screening Market Outlook, by Product, 2020-2033
5.3.3. Italy Blood Screening Market Outlook, by Technology, 2020-2033
5.3.4. Italy Blood Screening Market Outlook, by Product, 2020-2033
5.3.5. France Blood Screening Market Outlook, by Technology, 2020-2033
5.3.6. France Blood Screening Market Outlook, by Product, 2020-2033
5.3.7. U.K. Blood Screening Market Outlook, by Technology, 2020-2033
5.3.8. U.K. Blood Screening Market Outlook, by Product, 2020-2033
5.3.9. Spain Blood Screening Market Outlook, by Technology, 2020-2033
5.3.10. Spain Blood Screening Market Outlook, by Product, 2020-2033
5.3.11. Russia Blood Screening Market Outlook, by Technology, 2020-2033
5.3.12. Russia Blood Screening Market Outlook, by Product, 2020-2033
5.3.13. Rest of Europe Blood Screening Market Outlook, by Technology, 2020-2033
5.3.14. Rest of Europe Blood Screening Market Outlook, by Product, 2020-2033
5.4. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Blood Screening Market Outlook, 2020-2033
6.1. Asia Pacific Blood Screening Market Outlook, by Technology, Value (US$ Bn), 2020-2033
6.1.1. Nucleic Acid Amplification Test (NAT)
6.1.2. ELISA
6.1.3. Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)
6.1.4. Next Generation Sequencing
6.1.5. Western Blotting
6.2. Asia Pacific Blood Screening Market Outlook, by Product, Value (US$ Bn), 2020-2033
6.2.1. Reagent
6.2.2. Instrument
6.3. Asia Pacific Blood Screening Market Outlook, by Country, Value (US$ Bn), 2020-2033
6.3.1. China Blood Screening Market Outlook, by Technology, 2020-2033
6.3.2. China Blood Screening Market Outlook, by Product, 2020-2033
6.3.3. Japan Blood Screening Market Outlook, by Technology, 2020-2033
6.3.4. Japan Blood Screening Market Outlook, by Product, 2020-2033
6.3.5. South Korea Blood Screening Market Outlook, by Technology, 2020-2033
6.3.6. South Korea Blood Screening Market Outlook, by Product, 2020-2033
6.3.7. India Blood Screening Market Outlook, by Technology, 2020-2033
6.3.8. India Blood Screening Market Outlook, by Product, 2020-2033
6.3.9. Southeast Asia Blood Screening Market Outlook, by Technology, 2020-2033
6.3.10. Southeast Asia Blood Screening Market Outlook, by Product, 2020-2033
6.3.11. Rest of SAO Blood Screening Market Outlook, by Technology, 2020-2033
6.3.12. Rest of SAO Blood Screening Market Outlook, by Product, 2020-2033
6.4. BPS Analysis/Market Attractiveness Analysis
7. Latin America Blood Screening Market Outlook, 2020-2033
7.1. Latin America Blood Screening Market Outlook, by Technology, Value (US$ Bn), 2020-2033
7.1.1. Nucleic Acid Amplification Test (NAT)
7.1.2. ELISA
7.1.3. Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)
7.1.4. Next Generation Sequencing
7.1.5. Western Blotting
7.2. Latin America Blood Screening Market Outlook, by Product, Value (US$ Bn), 2020-2033
7.2.1. Reagent
7.2.2. Instrument
7.3. Latin America Blood Screening Market Outlook, by Country, Value (US$ Bn), 2020-2033
7.3.1. Brazil Blood Screening Market Outlook, by Technology, 2020-2033
7.3.2. Brazil Blood Screening Market Outlook, by Product, 2020-2033
7.3.3. Mexico Blood Screening Market Outlook, by Technology, 2020-2033
7.3.4. Mexico Blood Screening Market Outlook, by Product, 2020-2033
7.3.5. Argentina Blood Screening Market Outlook, by Technology, 2020-2033
7.3.6. Argentina Blood Screening Market Outlook, by Product, 2020-2033
7.3.7. Rest of LATAM Blood Screening Market Outlook, by Technology, 2020-2033
7.3.8. Rest of LATAM Blood Screening Market Outlook, by Product, 2020-2033
7.4. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Blood Screening Market Outlook, 2020-2033
8.1. Middle East & Africa Blood Screening Market Outlook, by Technology, Value (US$ Bn), 2020-2033
8.1.1. Nucleic Acid Amplification Test (NAT)
8.1.2. ELISA
8.1.3. Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)
8.1.4. Next Generation Sequencing
8.1.5. Western Blotting
8.2. Middle East & Africa Blood Screening Market Outlook, by Product, Value (US$ Bn), 2020-2033
8.2.1. Reagent
8.2.2. Instrument
8.3. Middle East & Africa Blood Screening Market Outlook, by Country, Value (US$ Bn), 2020-2033
8.3.1. GCC Blood Screening Market Outlook, by Technology, 2020-2033
8.3.2. GCC Blood Screening Market Outlook, by Product, 2020-2033
8.3.3. South Africa Blood Screening Market Outlook, by Technology, 2020-2033
8.3.4. South Africa Blood Screening Market Outlook, by Product, 2020-2033
8.3.5. Egypt Blood Screening Market Outlook, by Technology, 2020-2033
8.3.6. Egypt Blood Screening Market Outlook, by Product, 2020-2033
8.3.7. Nigeria Blood Screening Market Outlook, by Technology, 2020-2033
8.3.8. Nigeria Blood Screening Market Outlook, by Product, 2020-2033
8.3.9. Rest of Middle East Blood Screening Market Outlook, by Technology, 2020-2033
8.3.10. Rest of Middle East Blood Screening Market Outlook, by Product, 2020-2033
8.4. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Company Vs Segment Heatmap
9.2. Company Market Share Analysis, 2025
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. Abbott Laboratories
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Developments
9.4.2. Roche Diagnostics
9.4.3. Siemens Healthineers
9.4.4. Thermo Fisher Scientific
9.4.5. Bio Rad Laboratories
9.4.6. Danaher Corporation (Beckman Coulter & Cepheid)
9.4.7. Becton, Dickinson and Company (BD)
9.4.8. BioMérieux
9.4.9. Grifols, S.A.
9.4.10. Ortho Clinical Diagnostics
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations